VANI.NASDAQVivani Medical, INC
10-Q: Vivani Medical Reports Q1 2024 Results, Secures $13.7 Million in Financing
Sentiment:
Quarterly Report
Vivani Medical's Q1 2024 results show a net loss of $6.039 million, but the company secured $13.7 million in net proceeds from a securities purchase agreement.
Delay expectedThe LIBERATE-1 study for NPM-119 is on full clinical hold due to insufficient Chemistry, Manufacturing, and Controls (CMC) information.
Capital raiseThe company entered into a securities purchase agreement, raising $13.7 million in net proceeds.Vivani also entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $75 million of common stock.
Worse than expectedThe company reported a net loss of $6.039 million, indicating that it is not yet profitable and is still in the development phase.
Summary
- Vivani Medical, a preclinical stage biopharmaceutical company, reported a net loss of $6.039 million for the first quarter of 2024, which is slightly better than the $6.318 million loss in the same period of 2023.
- The company's operating expenses totaled $6.227 million, with research and development expenses at $3.726 million and general and administrative expenses at $2.501 million.
- Vivani secured $13.7 million in net proceeds from a securities purchase agreement, issuing 3,947,368 shares of common stock and warrants.
- The company's cash and cash equivalents increased to $29.648 million as of March 31, 2024, up from $20.654 million at the end of 2023.
- Vivani estimates that its current cash will be sufficient to fund operations into the second half of 2025.
- The company is focused on developing its NanoPortal technology for long-term drug delivery, particularly in the area of GLP-1 implants for weight management.
- A clinical hold remains on the NPM-119 program due to insufficient Chemistry, Manufacturing, and Controls (CMC) information, which the company aims to address in the first half of 2024.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company has made progress in its preclinical programs and secured significant funding, it is still operating at a loss and faces regulatory hurdles. The clinical hold on NPM-119 is a concern, but the positive preclinical data for NPM-115 and the focus on the obesity portfolio are encouraging.
Positives
- The company's net loss decreased slightly compared to the same quarter last year.
- Vivani secured a significant capital raise of $13.7 million, strengthening its financial position.
- Preclinical data for NPM-115 showed weight loss results comparable to semaglutide, a leading obesity treatment.
- The company is prioritizing its obesity portfolio, which has significant market potential.
- Vivani has established a subsidiary in Australia to support its clinical studies.
Negatives
- The company continues to operate at a loss, with a net loss of $6.039 million for the quarter.
- The NPM-119 program is on clinical hold due to insufficient CMC information.
- The company is still in the preclinical stage and has no revenue.
- Vivani is dependent on raising additional capital to fund its operations.
- There is ongoing litigation with Pixium Vision SA, which could result in additional costs.
Risks
- The company is subject to the risks and uncertainties associated with a business with no revenue that is developing novel medical devices.
- Vivani has incurred recurring operating losses and negative operating cash flows since inception, and expects to continue to do so.
- The company's ability to continue as a going concern is dependent on its ability to raise additional capital and/or develop profitable operations.
- The clinical hold on the NPM-119 program could delay its development and commercialization.
- The ongoing litigation with Pixium Vision SA could result in significant financial liabilities.
- The company's success is dependent on the successful development and commercialization of its product candidates, which is not guaranteed.
Future Outlook
Vivani estimates that its current cash will be sufficient to fund operations into the second half of 2025. The company plans to continue developing its drug implant portfolio, particularly in the area of GLP-1 implants for weight management. Vivani also intends to address the clinical hold on the NPM-119 program in the first half of 2024.
Management Comments
- Vivani's management team remained committed to identifying and exploring strategic options that will enable further development of its pioneering neurostimulation systems from legacy company Second Sight.
- Moving forward, Vivanis focus will be on the further development of NPM-115 and its emerging pipeline of innovative miniature, long-term drug implants to treat patients with chronic diseases and high unmet medical need.
Industry Context
The company's focus on long-term drug delivery, particularly in the obesity market, aligns with the growing demand for more convenient and effective treatments for chronic diseases. The development of GLP-1 implants is a significant area of interest, given the success of drugs like Ozempic and Wegovy. The company's technology aims to address medication non-adherence, a major challenge in chronic disease management.
Comparison to Industry Standards
- Vivani's preclinical results for NPM-115, showing approximately 20% weight loss in mice, are comparable to the results seen with semaglutide injections (Ozempic/Wegovy) in the same study, indicating a potential for competitive efficacy.
- The company's focus on long-term, subdermal implants aligns with the industry trend towards more convenient drug delivery methods, similar to companies developing implantable devices for other chronic conditions.
- The clinical hold on NPM-119 highlights the challenges in developing novel drug delivery systems, which is a common hurdle for companies in this space. Companies like Intarcia Therapeutics have faced similar challenges in the past.
- Vivani's financial position, with $29.648 million in cash and cash equivalents, is relatively strong for a preclinical stage company, but it will need to continue to raise capital to fund its development programs, similar to other biotech companies in the early stages of development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | Daniel Bradbury | 2024-03-06 | New appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Non-Employee Director Compensation Policy | The annual cash retainer fees for non-employee Directors were set effective September 1, 2022, with options to receive the equivalent in stock options. | 2022-09-01 | Provides a framework for compensating non-employee directors and aligns their interests with shareholders. |
Legal Proceedings
- An opposition filed by Pixium Vision SA is pending in the European Patent Office challenging the validity of a European patent owned by Cortigent.
- Vivani is involved in ongoing litigation with Pixium Vision SA related to the termination of a Memorandum of Understanding, with Pixium claiming damages of approximately $5.6 million.
- The Paris Commercial Court has opened liquidation proceedings against Pixium, and Pixium's liquidator has intervened in the pending proceedings before the Paris Court of Appeal.
Related Party Transactions
- Vivani has agreed to advance funds and provide services to Cortigent, a wholly-owned subsidiary, until the earlier of December 31, 2024, or the closing of an initial public offering of Cortigent.
- Cortigent has agreed to repay $1.5 million to Vivani at the conclusion of the funding support term and will enter into a five-year promissory note at 5% interest for $2 million in favor of Vivani.
Stakeholder Impact
- Shareholders will be impacted by the dilution from the issuance of new shares and warrants.
- Employees may be affected by the company's ongoing efforts to conserve cash, including potential reductions in force.
- Customers and patients may benefit from the development of new drug delivery technologies, but the clinical hold on NPM-119 could delay access to new treatments.
- Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.
Next Steps
- Vivani plans to provide the FDA with the requested CMC information to address the clinical hold on NPM-119 in the first half of 2024.
- The company will continue to develop its lead program, NPM-115, and its emerging pipeline of long-term drug implants.
- Vivani will continue to explore strategic options for its neurostimulation systems.
- The company may sell shares of common stock under the Open Market Sale Agreement with Jefferies LLC.
Key Dates
| Date | Description |
|---|---|
| 2019-12-31 | NPM issued common stock and warrants. |
| 2020-12-31 | NPM issued common stock and warrants. |
| 2021-04-01 | Vivani terminated the MOU with Pixium. |
| 2021-12-31 | NPM issued common stock and warrants. |
| 2022-08-30 | Second Sight and NPM merger closed, forming Vivani Medical, Inc. |
| 2022-11-07 | Non-Employee Director Compensation Policy adopted. |
| 2022-11-19 | Vivani entered into a lease agreement for a building in Alameda, California. |
| 2022-12-08 | Vivani received notice of the Paris Commercial Court judgment regarding the Pixium MOU termination. |
| 2022-12-31 | End of fiscal year. |
| 2023-01-23 | Vivani entered into a lease for storage space. |
| 2023-01-31 | Vivani entered into a lease agreement to sublease office space. |
| 2023-02-01 | Sublease of office space became effective. |
| 2023-03-19 | Transition Funding, Support and Services Agreement between Vivani and Cortigent. |
| 2023-03-21 | Pixium's liquidator filed a brief with the Paris Court of Appeal. |
| 2023-03-31 | End of Q1 2023. |
| 2023-05-24 | Vivani filed an appeal against the Paris Commercial Court judgment. |
| 2023-06-15 | Vivani's stockholders approved the reincorporation to Delaware. |
| 2023-07-05 | Vivani changed its state of incorporation to Delaware. |
| 2023-07-14 | Vivani filed an IND for NPM-119 with the FDA. |
| 2023-08-18 | FDA placed a clinical hold on the LIBERATE-1 study. |
| 2023-08-25 | Vivani and Cortigent entered into Amendment 1 to the TFSSA. |
| 2023-09-28 | Vivani entered into a sublease for office space in Valencia, California. |
| 2023-10-09 | Paris Commercial Court opened safeguard proceedings against Pixium. |
| 2023-11-13 | Paris Commercial Court converted Pixium's safeguard proceedings into receivership. |
| 2023-12-31 | End of fiscal year. |
| 2024-01-18 | Pixium filed a cross-appeal with the Paris Court of Appeal. |
| 2024-01-31 | Paris Commercial Court converted Pixium's receivership proceedings to liquidation proceedings. |
| 2024-02-28 | Vivani entered into a securities purchase agreement. |
| 2024-03-01 | Vivani entered into a securities purchase agreement with an institutional investor. |
| 2024-03-05 | Vivani received gross proceeds from the securities purchase agreement. |
| 2024-03-21 | Pixium's liquidator filed a brief with the Paris Court of Appeal. |
| 2024-03-31 | End of Q1 2024. |
| 2024-04-17 | Vivani filed its brief in reply with the Paris Court of Appeal. |
| 2024-04-22 | Vivani entered into an Open Market Sale Agreement with Jefferies LLC. |
| 2024-05-03 | Vivani's Registration Statement on Form S-3 was declared effective. |
| 2024-05-10 | Date of share count disclosure. |
| 2024-05-13 | Date of filing of the 10-Q. |
Keywords
biopharmaceutical, drug delivery, GLP-1 implant, obesity, weight management, NanoPortal technology, clinical hold, securities purchase agreement, preclinical, semaglutide
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.